TransCon CNP (navepegritide) — Regulatory decision
Q4 2026
The final European Commission (EC) decision on Ascendis' Marketing Authorisation Application (MAA) is expected during Q4 2026.Source filing
ASND biotech catalysts & pipeline
ASCENDIS PHARMA A · Data as of 2026-10-25